In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

Marguerite L. Monogue; Jennifer Tabor-Rennie; Kamilia Abdelraouf; David P. Nicolau

doi:10.1128/AAC.00233-19

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

Marguerite L. Monogue, Jennifer Tabor-Rennie, Kamilia Abdelraouf, David P. Nicolau

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log₁₀ CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

Original language	English (US)
Article number	e00233-19
Journal	Antimicrobial agents and chemotherapy
Volume	63
Issue number	7
DOIs	https://doi.org/10.1128/AAC.00233-19
State	Published - 2019

Keywords

Human simulated
Pharmacodynamics
Pharmacokinetics

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.00233-19

Cite this

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model. / Monogue, Marguerite L.; Tabor-Rennie, Jennifer; Abdelraouf, Kamilia et al.
In: Antimicrobial agents and chemotherapy, Vol. 63, No. 7, e00233-19, 2019.

Research output: Contribution to journal › Article › peer-review

@article{ba6313da29dd49d392bb27c0d45ae77c,

title = "In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model",

abstract = "We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.",

keywords = "Human simulated, Pharmacodynamics, Pharmacokinetics",

author = "Monogue, {Marguerite L.} and Jennifer Tabor-Rennie and Kamilia Abdelraouf and Nicolau, {David P.}",

year = "2019",

doi = "10.1128/AAC.00233-19",

language = "English (US)",

volume = "63",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "7",

}

TY - JOUR

T1 - In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

AU - Monogue, Marguerite L.

AU - Tabor-Rennie, Jennifer

AU - Abdelraouf, Kamilia

AU - Nicolau, David P.

PY - 2019

Y1 - 2019

N2 - We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

AB - We describe the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) exposure against multidrug-resistant Pseudomonas aeruginosa (meropenem MICs 8 to 256 g/ml) in a neutropenic murine thigh infection model. WCK 5222 MICs ranged from 4 to 32 g/ml. Substantial in vivo WCK 5222 activity was observed against all isolates, further enhancing the efficacy of zidebactam alone in 11/16 isolates (WCK 5222 mean reduction, –1.62 0.58 log10 CFU/thigh), and a lack of activity was observed with cefepime monotherapy.

KW - Human simulated

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85068136678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068136678&partnerID=8YFLogxK

U2 - 10.1128/AAC.00233-19

DO - 10.1128/AAC.00233-19

M3 - Article

C2 - 31235557

AN - SCOPUS:85068136678

SN - 0066-4804

VL - 63

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 7

M1 - e00233-19

ER -

In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this